Valuation: BioNTech SE

Market Cap 2.44TCr 2.84TCr 2.28TCr 2.09TCr 3.93TCr 2,71600Cr 3.99TCr 27TCr 11TCr 1,36200Cr 11TCr 10TCr 4,50400Cr P/E 2026 *
-17.6x
P/E 2027 * -18.7x
Enterprise Value 1.3TCr 1.52TCr 1.21TCr 1.11TCr 2.1TCr 1,44900Cr 2.13TCr 14TCr 5.61TCr 73TCr 5.69TCr 5.57TCr 2,40300Cr EV / Sales 2026 *
7.2x
EV / Sales 2027 * 7.78x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.19%
Current month+5.40%
Current year+5.40%
3 years 88.76
Extreme 88.76
115.95
5 years 86.62
Extreme 86.62
335
10 years 11.5
Extreme 11.5
396.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%+20.06% - - 2.84TCr
+2.38%+5.57%+86.02%+115.89% 7.22TCr
+0.87%+17.34%+57.17%+94.08% 6.4TCr
-2.64%+0.86%-1.57%+479.18% 2.85TCr
+3.63%+8.62%+66.69%+23.95% 2.51TCr
-1.29%+19.34%-1.23%-6.46% 2.84TCr
-0.51%+5.73%+38.71%-14.19% 2TCr
-1.79%-4.51%+241.26%+414.48% 1.82TCr
+1.81%+0.85%+16.89%+546.06% 1.6TCr
-0.22%+7.25%+43.37%+154.00% 1.35TCr
Average +0.11%+5.63%+60.81%+200.78% 3.18TCr
Weighted average by Cap. +0.50%+7.48%+61.15%+162.74%

Financials

2026 *2027 *
Net sales 180.71Cr 210.66Cr 168.74Cr 154.81Cr 291.13Cr 20TCr 295.92Cr 1.99TCr 779.67Cr 10TCr 791Cr 773.79Cr 33TCr 184.35Cr 214.91Cr 172.14Cr 157.93Cr 296.99Cr 21TCr 301.88Cr 2.03TCr 795.38Cr 10TCr 806.94Cr 789.38Cr 34TCr
Net income -134.84Cr -157.19Cr -125.91Cr -115.52Cr -217.23Cr -15TCr -220.8Cr -1.49TCr -581.76Cr -7.54TCr -590.21Cr -577.37Cr -25TCr -131.32Cr -153.08Cr -122.62Cr -112.5Cr -211.55Cr -15TCr -215.04Cr -1.45TCr -566.56Cr -7.34TCr -574.8Cr -562.29Cr -24TCr
Net Debt -1.14TCr -1.33TCr -1.06TCr -973.96Cr -1.83TCr -1,26700Cr -1.86TCr -13TCr -4.9TCr -64TCr -4.98TCr -4.87TCr -2,10100Cr -1TCr -1.17TCr -936.66Cr -859.36Cr -1.62TCr -1,11800Cr -1.64TCr -11TCr -4.33TCr -56TCr -4.39TCr -4.3TCr -1,85300Cr
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
20/26/20 93.55 -3.21% 19,919
19/26/19 €96.65 +20.51% 46,226
18/26/18 €80.20 +1.20% 1,812
17/26/17 €79.25 -1.55% 746
14/26/14 €80.50 +0.88% 1,182
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
97.03EUR
Average target price
104.04EUR
Spread / Average Target
+7.22%

Quarterly revenue - Rate of surprise